Earnings Call: Q4 2018

Nov 7, 2018

Good day, ladies and gentlemen, and welcome to your Ashland Global Holdings, Incorporated 4th Quarter Earnings Call. At this time, all participants As a reminder, today's conference is being recorded. I would now like to turn the call over to Seth Mrozek. Sir, you may begin. Thank you, Sydney. Good morning, everyone, and welcome to Ashland's 4th quarter fiscal 2018 earnings conference call and webcast. My name is Seth Marissak, director, Ashland Investor Relations. Joining me on the call today are Phil Wilson, Ashland's Chairman and Chief Executive Officer and Kevin Willis, Senior Vice President And Chief Financial Officer. We released preliminary results for the quarter ended September 30, 2018 shortly after 5 pm Eastern Time yesterday, November 6th. Additionally, we posted slides to our website, ashland.com, under the Investor Relations section, and have furnished each of these documents to the SEC in a form 8 K. As a reminder, during today's call, we will be making forward looking statements on a number of matters, including our financial fiscal year 2019. These forward looking statements are subject to risks and uncertainties that could cause future results or events to differ materially from today's projections. We believe any such statements are based on reasonable assumptions, but cannot assure that such expectations will be achieved. Please refer to yesterday's slide presentation for a fuller explanation of those risks and uncertainties and the limits applicable to forward looking statements. Please also note that we will be referring to certain actual and projected financial metrics on Ashland on an adjusted basis, which are non GAAP financial measures. We will refer to these measures as adjusted and present them in order to supplement your understanding and assessment of the financial performance of our ongoing business. Non GAAP measures should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP. The most directly comparable GAAP measures as well as reconciliations of the non GAAP measures to those GAAP measures are available in and on our website and in the appendix of yesterday's slide presentation. With that, I will turn the call over to Bill. Good morning, everyone, and thank you for calling into Ashland's 4th quarter fiscal year 2018 earnings call. 18 months ago, having just completed the Valvoline separation, we presented our Investor Day thesis, which included 3 performance targets driven by 7 core operating lovers. We have now completed our 1st full fiscal year, and I'm pleased to share clear evidence that our value creation plan is working. The following are a few highlights as evidence of our progress towards our financial goals. Our first Investor Day financial objective was to grow EPS at a level greater than 15% per year. In fiscal year 2018, we grew EPS by 47%. We also set the objective to increase ASH guidance to 25% to 27%. In the 4th quarter, we achieved adjusted EBITDA margins of 25.2 percent, our highest in 6 years. And for the full fiscal year 2018, margins rose 100 basis points to 23.2 percent when compared to fiscal year 2017. Finally, on an adjusted basis, we delivered free cash flow of $159,000,000, which includes 39,000,000 of restructuring payments, which puts us well in line with our target to generate $1,000,000,000 or more of free cash flow over the plan period. Now getting a bit more granular within ASI, revenue was up for the year, 11% or 4%, excluding the impact of currency divestitures and acquisitions. Personal care sales rose 4% driven by a very strong year for innovative bio functional skin and hair care technologies. Pharma is up 11% due to incremental sales from our new Klucel capacity and are successful CMC debottlenecking activities. Adhesives sales rose 5% for the year, largely driven by healthy pricing and strong product mix improvements. Coatings rose 5% as we sustained strong relationships with our key coatings customers and continued to drive innovation with the successful launch of Aquaflow XLS. And we also expanded our Nanjing capacity by roughly 30%. Construction Energy And Performance Specialties was up 9% for the year, driven by improving market conditions. And finally, nutrition and other climbed 8% due to focused asset utilization programs. For the full fiscal year, ASI's adjusted EBITDA margin grew 100 basis points to 23.2 percent in the context of approximately $40,000,000 of raw material inflation. Multiple product launches to improve product mix and profitability, targeted volume initiatives to drive positive disruption, and reduced spending leading to adjusted SG and A being approximately a 130 basis points lower than prior year. Finally, we had great success integrating Pharmachem and upgrading the mix, allowing us to improve margins and free up capacity to grow sales from a more profitable base. In Q3 you saw improved year over year pharmachem EBITDA margins. Before corporate allocations, they were approximately 30%. In Q4, those margins again expanded up almost 1000 basis points year over year to 33% and pharma chem sales rose 6% year over year. So for the full year, Farmichem delivered $65,000,000 in adjusted EBITDA, excluding corporate allocations. And this was in line with our expectations for the business for the year. Taken altogether, these actions delivered $574,000,000 in adjusted EBITDA for a, ASI. This is a 16% increase over prior year and a 9% increase without FX, acquisitions and divestitures. Also noteworthy in fiscal year 2018, Composites and INS reported very strong results. Within composites, sales grew 21% while adjusted EBITDA came in at 95,000,000 which was up 7%. Within INS sales climbed 25% and adjusted EBITDA finished at 61,000,000 up 135% from prior year. In addition, during the year, we kicked off a plan to sell our composites and model INS business with the objective of completing our path to becoming a pure specialty chemical company. This action remains on track as we work to complete a competitive process. We also took proactive actions to offset stranded costs related to composites and model sale and to accelerate EBITDA margin improvement by 200 basis points in ASI. In total, we announced a $120,000,000 cost take up program. This program, which is also intended to make us a more nimble customer focused growth oriented organization, is fully on track. We met our first major milestone by capturing the targeted $20,000,000 in annualized run rate savings by the end of the September quarter. Note that Specialty Ingredients adjusted SG and A spend in Q4 was down 5% versus prior year. We have now completed our organization redesign and are on track with all cost savings we remain on track to be at a $50,000,000 annualized run rate by the end of the calendar year and are on schedule to deliver for $120,000,000 of run rate savings by the end of calendar 2019. So when you bring this all together, Ashland Delivered very strong results in fiscal year 2018. In the aggregate, sales rose 15 percent to 3,700,000,000 Excluding currency and acquisitions, sales grew 7%. We offset significant raw material inflation through pricing actions, mix optimization, and a successful focus on asset utilization absorption. Adjusted SG and A was down 130 basis points versus prior year. All three segments met or exceeded the outlook ranges we presented at the beginning of the year. Adjusted EBITDA rose 20 percent to $683,000,000, And as I mentioned before, adjusted EPS climbed 47%, which is far above the 15% target we outlined at our Investor Day of last year. The results of these efforts can be seen in our stock performance versus the S and P 400 when you look at it on a 1 year basis a 3 year basis or a 5 year basis. Finally, in referencing fiscal year 2018, I'd like to finish with a key accomplishment achieved on our founding principle, which is safe and responsible operations. Now you may recall during our last call, I shared that Ashland was recognized as the American chemistry council's responsible care of the year. In addition, Tonight, Ashland will be named 1 of America's safest companies for 2018 by EHS today, the magazine for EHNS Leaders. While we will never be satisfied until we achieve our vision of 0 incidents, we are proud of the important work being done by our global teams to promote a 0 incident culture at Ashland, and we do appreciate this recognition. So in conclusion, I believe in fiscal year 2018, we demonstrated that 1, we have a strong plan for value creation 2, we are proactively taking aggressive action to accelerate results. 3, the team is executing at a high level And 4th, as a result, we are creating significant comparative value for our shareholders. I will now turn the call over to Kevin for a closer look at fiscal year 2018 financials and our fiscal year 2019 outlook. Thank you, Bill, and good morning, everyone. First, let's start with Ashland's results in the 4th quarter. Sales in the quarter were $956,000,000, up 9% from the year ago period. Adjusted EBITDA in the quarter was $179,000,000, up 11% year over year. In the quarter, we reported U. S. GAAP earnings from continuing operations of $0.17 per diluted share. On an adjusted basis, we reported income from continuing operations of $0.97 per diluted share compared to $0.78 in the prior year. This compares to our outlook at the beginning of the quarter of $0.90 $1 per share. Free cash flow during the fourth quarter was $131,000,000 compared to $69,000,000 in the prior year. These amounts include $2,000,000 in restructuring costs in the fourth quarter of fiscal 2018 $3,000,000 of restructuring in the year ago period. Our effective tax rate for the fourth quarter after adjusting for key items was 16% compared to 6% in the prior year period. Now for an update on the sale process for composites in the Marl BDO facility. The process continues to be competitive and remains on track and our There has been strong interest from potential buyers throughout the process, and we look forward to sharing more information when a definitive agreement is finalized. Turning to the balance sheet. We've made excellent progress reducing our leverage since the Pharmachem acquisition in mid-twenty 17. In fiscal 2018, we reduced our gross debt to adjusted EBITDA by over return to 3.7 times. Our target for gross debt to EBITDA following the planned composites and model divestiture remains about 2.5 times EBITDA. We expect to achieve this during Our thinking around use of proceeds from the composites and Marl divestiture hasn't changed, primarily debt reduction. Now, I'd like to spend some time on our financial outlook for fiscal 2019, which we published in our release materials last night. Note that our outlook for fiscal 2019 is provided on a current operations We plan to update expect the following fiscal 2019 adjusted EBITDA ranges for each of our current reportable segments $610,000,000 to $635,000,000 for specialty ingredients, $95,000,000 to $105,000,000 for composites, $55,000,000 to $65,000,000 for INS, and we would expect to have around $40,000,000 to $50,000,000 of corporate and unallocated other costs. Consistent with fiscal 2018, we plan to update these outlook ranges throughout the year. Within specialty ingredients, we expect continued growth in Pharma, our highest margin business, as well as our industrial businesses. In personal care, we expect continued growth in our skin and hair care end markets. However, we expect reduced demand in the oral care end market. Within oral care, Colgate is an important customer, and they are relaunching their total toothpaste brand with a different antibacterial ingredient that does not require our Gantres or any other bio adhesive. This relaunch could impact specialty ingredients annual sales by as much as 1%. In spite of this isolated item, we expect to grow specialty ingredient sales by 2% to 3% in fiscal 2019. This sales growth combined with $20,000,000 of cost savings from the restructuring program is expected at the midpoint of our range to deliver approximately 8% EBITDA growth in fiscal 2019. We are very confident we can continue to leverage the playbook from fiscal 2018 to deliver solid execution, driving mix improvements a focused pipeline of new value creating products, asset utilization and aggressive pricing actions. For the full year, we expect Ashland's adjusted EPS to be in the range of $4.20 This assumes an effective For the first quarter, we expect adjusted compared to $0.42 per diluted share in the prior year period. This assumes an effective tax rate of 16% in the first quarter. Remember that the December quarter is our seasonally slowest from a commercial and manufacturing standpoint. We expect free cash flow of approximately $230,000,000 and restructuring related costs. As we communicated at our May 2017 Investor Day, our free cash flow objectives are net of any separation or restructuring related costs. Now, I'll turn the call back over to Bill. Thank you, Kevin. So in summary, we defined a plan during our Investor Day in 2017. We have a strong team focused on disciplined execution. We're taking aggressive and proactive action The plan was effectively implemented in fiscal year 2018 and led to significant value creation for shareholders. Looking to fiscal year 2019, for ASI, we expect to deliver 2% to 3% organic revenue growth, We expect to continue to improve EBITDA margins through innovation value selling and better asset utilization and this combined with $20,000,000 of cost savings from the $50,000,000 ASI restructuring program is expected to deliver at the midpoint of our range approximately 8% EBITDA growth. In addition, we intend to complete the sale of the composites business in the Marrow BDO facility, while implementing programs to eliminate roughly $70,000,000 of related stranded costs. In closing, the Ashland team delivered in fiscal year 2018, and we intend to deliver again in fiscal year 2019. And with that, we'll open questions. To prevent any background noise we ask that you please Our first question comes from Christopher Parkinson with Credit Suisse. Your line is open. Thanks. Given your guidance of 20,000,000 in cost savings, for ASI embedded in guidance for next year. Can you just talk about the initial buckets of savings in that number And then breakdown ASI's benefit from 4Q. I think naturally, you know, all the sell side is greedy in terms of the cadence of the remaining $30,000,000 for the total of $50,000,000 over time. But you just kind of just break down what's, you know, in your control over the intermediate term, the initial progress, and maybe just very quickly on the longer term opportunities of procurement and SAP once ASI is a standalone entity. Thank you. Sure. Sure. Thank you for the question. And we feel great about the progress that's been made. First of all, on delivering the initial milestone of $20,000,000 run rate by the beginning of the fiscal year. We have roughly about half of the savings within ASI would be headcount related and half of it would be in indirect or manufacturing related costs. We have defined the actions which we intend and are in the process of implementing And in fact, we have work to communicate throughout the organization, the changes that we are making. And with that, we feel like we are strongly on track for the $50,000,000 run rate by twelvethirty 1eighteen. And then the remainder will be achieved throughout, if you will, the rest of the fiscal year with the benefit being fully realized, we'll say in calendar 2019. And, Chris, the the the the plan, the plans are, are done. We've we've communicated internally with the vast majority of of our employees, whether they're impacted or not by, by the restructuring. So people know where they stand. And really, it's, it's all about implementation at this point. And will come sooner rather than later. In terms of what we saw in Q4 for the corporation, realized savings is probably in the range of, call it, $3,000,000, $4,000,000, again, across the corporation. And that's partly, partly in corporate, partly in the ingredients business. But we're very confident about our ability to deliver on this. We've got solid plans. Everybody understands their accountability around those plans. And we're prepared to track and manage that very, very closely and carefully throughout the course of this fiscal year. This is not a new process for us. We've done this many times as we bought and sold businesses and have a high degree of confidence that that we'll get this done. And one other point just to add and it's really to emphasize is we've defined the actions and we have, set them up with, if you will, milestone dates We have owners and we have a process to track not only the actions and the implementation, but to track the effectiveness, if you will, flowing through the P and L. Got it. And just a quick follow-up. On the Pharmachem front, there's, you know, there's a little bit of noise and maybe a little investor skepticism over the last, you know, let's say 5 or so quarters. But the pre corporate expense margin of 33 percent is quite frankly surprising, but a pleasant one at that. Can you walk us through just the quarter, the cost improvements, just what you were going through the implementation process there? And then just how we should think about the pre corporate margins into 2019 and just any update on how you're thinking about the NNH part of that versus the FNF or FNB? Thank you. You bet. You bet. And again, we're very pleased. We had a strategy with the business when we brought it on board. It's a great business it's a great complement to what it is we do in our, our core. I'd love to talk about some of the, the synergies that we're we're seeing on the commercial front and so forth, but more specifically to your question, we we did exit what we would consider to be some lower margin less attractive business we fundamentally lowered the SG and A. Part of that was within the business, part of that was related to the synergies that are associated with bringing the business into Ashland. And then we focused on growing the business with a more differentiated and higher margin mix And again, while we don't include this in the numbers, we are using their assets now to help us produce products, which we otherwise had limited capacity and would have had told. So we, we've progressed on track. You see the margin improvement that's taken place throughout the year and the contribution And so we saw a lot of momentum building as we as we finished the fiscal year. And we we expect that strength to continue In addition, from a, from a synergy standpoint, we were able to move the Voca portion of the business onto our SAP and we'll work on moving the remainder of Pharmachem on SAP this year. And that's very important because that will help to unlock additional if you will, cost based synergies once we have that in place. So and I'm happy to go into more detail about the respective synergies, but I hope that answers your question. That does very good detail. Thank you. Thank you. Our next question comes from John McNulty with BMO Capital Markets. Your line is now open. Yeah. Thanks for taking my question. Look, the the pharma business was you you had some capacity expansions. You had Klucel, expanding. I guess when you and you saw some really solid growth in that segment. I guess I'm wondering how should we think about what the normalized growth for that business is at this point, or put another way when you when we get through kind of the annualizing of the capacity ramp, what should we be thinking about in terms of growth there? Because I think there may have been some pent up demand. And I guess we're trying think about what what normal might be for that? You bet. And as we shared in our Investor Day, 5% growth would be a reasonable target for that business. You're, you're right, there was pent up demand for these products. And and what we're we're seeing is that as we we are able to produce the quantity, the quality on time with our customers that there is significantly greater interest. So I would say 5% would be a good number to castimate. But at the same point, we're cautiously optimistic that, that there may be opportunities to grow that portion of the business a more accelerated rated base or rate at a on a more sustained basis. And, John, the other the other thing I would add that. Cluesell has been a really important capacity expansion for us. We've seen really, really solid uptake on on that on that improved capacity. But I I would also mention our Benecel capacity at dual Belgium, our ability to to produced those those pharma grade products at Dual, with incredibly high produced as intended rates have been very well accepted by customers. And that's that's also That's also helped our pharma growth this year. And we'd expect that to also contribute, in in the coming years as well. And that's, that's just one those examples of the asset utilization program where a focused effort has allowed us to take existing equipment and just get on not only a higher grade, but a lot more productivity from it given us the opportunity to grow. Got it. No, that's that's helpful. And then I guess on the ASI side, I think there was some commentary in the deck around the price versus cost. And while you got some pricing, cost inflation, more than offset that. I guess, what were the major buckets in terms of the cost pressures? And I guess, how should we think about your ability to catch up with regard to price on that? Yeah. I'll answer your second question first. As you as you look at ASI, it it depends on the end market, but generally, it's 1 to 2 quarters of lag to actually get caught up on price. And as as you're well aware, we've been talking about it for quite a while. We've And we've seen continued, you know, continued raw material cost pressure. We we do have a fair amount of of crude derived raws And so that's, you know, that that's something to watch. We have seen crude come off. We we have to work through our higher cost inventories before we'll actually see the benefit of that. But over the course of the next quarter or 2, we'll get that done and we should assume include stays at current levels, we should start to see some some benefit from that. We've we've also seen cost pressure from a transportation perspective as have most companies. We we we see the cost of of shipping, not only in the US, but in other parts of the world, increasing as Ironically, GDP has increased. There's been, you know, a bit of a bit of a shortage of of over the road trucks and drivers. And so we've We've seen some cost inflation from from that as well. I don't wanna overplay that, but that's, you know, that that's definitely been in there. And so that's that's kind of where we are. I I would say that, we've we have developed really strong processes internally with with the Salesforce. And with our ability to track what actually happens from a cost versus price perspective. And we're leveraging that to hold the team accountable for driving improved pricing, not only where we we see cost pressure, but otherwise. And and just to to add, certainly, the price versus raw is an extremely important area that we are focusing a lot of energy on. We feel great about the progress that we have made as it relates to the rum to inflation we saw last year. More work to be done. At the same time, I want to continue to emphasize the theme that we hold our commercial teams accountable for their commercial contribution, which includes the volume, the mix, the absorption, the price versus raws, and and as a team, what we have done is focused on how do we deliver the results in the aggregate and and not look for, for example, you know, we had 40,000,000 of raw material inflation last year. We're we're talking about that because of our unplanned. We're talking about that because it comes up in the question. But you know, we we haven't been wearing that that on our sleeve as a reason for not delivering or delivering at a different level. So we'll continue to work on price, but the team has an attitude that there are multiple avenues to improve our profit contribution and in certain parts of the cycle, some will be more favorable and other parts will have to pull harder in other areas. Great. Thanks very much. Thanks, John. Thank you so much. Our next question comes from David Begleiter with Deutsche Bank. Your line is now open. Thank you. Good morning. Bill and Kevin, on the ASI guidance of mid single digit growth for 2019, what would it be if you back out or just for FX and a loss of the business at Colgate? Would it be upper would be 10% growth or in that range? Yeah. Kevin can speak to the the FX portion in a moment. What I I would say as it relates to the Colgate Businesses and and in the personal care business that it is a business that you have wins and losses, this one is noteworthy because it's it's important, at the, at the same time, we intend to grow our our hair and skin care. We expect to grow in other areas. We're working to manage our plant related costs. So we built our plans with, if you will, or a forecast here as we communicate with you today with a full integration of the the Colgate dynamic as we see it. So it's a little bit hard for me to back that out because, while it makes a contribution, it's It is, it is, or there are actions taking place. But to put it in perspective, the GP associated with that is roughly equal to 1 quarter of the raw material inflation that we've cited before. And so with that in mind, while it is, an important dynamic just as we were able to manage through through the raw material inflation last year. This is something which we will manage through this year. Yeah. FX is probably is probably about a point would be my would be my guess based on where we are right now. And that's, you know, that's a dollar 19 verse a dollar 15 for the for the euro. And and, you know, they'll they'll kind of size the the the Colgate piece already. So call it between between the two, it's probably a point or 2 that that that, you know, might be accretive if, you know, if, if, if that, if those things were, were not in play. And maybe just to, to finish up in personal care in Q4, just to put in perspective, we, we saw a weakness in the oral care market, which offset the gains we had in the hair and skin care. And And while we don't report by by market, if you will, we actually saw a significant, significant margin improvement within the business because they focused on, if you will, a more premium mix with the file functionals and so forth. And so actually while sales were flat to business, or that portion of the business actually earned more money Got it. And just on the overall cost structure, Bill and Kevin, now that you're into maybe wave 1 of the cost reduction program, What are you thinking about maybe a wave 2 of additional actions given the large amount of costs embedded in the company? You bet. And of course, we've looked with an open mind at the opportunities, both short term and long term. The $120,000,000 is a big number for us to make sure that we successfully bring into the P and L over this, if you will, 18 month period. And and it is related to a lot of change. We are in a growth mode and we want to sustain the team's ability to actually enhance our team's ability to grow. And so as we look to potentially more actions in the future. I would say that, there'll be more structural in nature. And what I mean I mean, for example, if we as we get everybody on one common SAP and potentially provide some enhancement to that system, that might free up the ability to do, do things in a more productive way. So we will talk down the road about additional thoughts on cost reduction, it will continue to be a major focus for the company, but but frankly, delivering on this $120,000,000 is the core focus right now. And so I'd like to Day, if you will, the team, with the team executed at a high level on on that. Yeah. And just to, I think, just to maybe provide just a little more perspective, ex ex restructuring. We're when we're done with this, you know, presuming, you know, presuming a a, you know, composites and Marl divestiture And we're, you know, we're we're gonna be taking, you know, we're gonna be taking SG and A as a percent of sales down, a fair bit. And the thing you gotta keep in mind in the ingredients business is we've got approximately $90,000,000 of deal related DNA running through SG And A. And that doesn't go away. So you think about that on 2.6,2.7000000000 of revenue, that's 3a half or so percent of of sales. So you you really need to think about SG And A net of that when you when you look at the business and compare us to whatever peer group you want to compare us to. So just to put that in perspective, if you exclude that, intangible and the 15% to 15% rate, after where we take the $50,000,000 of cost out. So we think we'll be very competitive, if you will, presuming, yeah, presuming, yeah, presuming growth rates that we've that we're projecting. That's right. Thank you very much. Sure. Thank you. Our next question comes from the line of Mike Sison with KeyBanc. Hey, guys. Congrats on a, a good year and end of the year. Bill, when you think about ASI, you've talked about getting to 25%, you got there. Congrats on that. Given the potential for a phase 2 of cost savings, as you just noted. Any current, any updated thoughts on where you think margins you know, could be and and clear you wanna grow the business. So, you can't just cut your way to to the next level. But any any of your current thoughts to where you think ASI EBITDA margins could go from here? Yes. Certainly. And, as proud as we are of that, 25% plus if you will result in Q4. We do have some seasonality to the business. We were able to improve the business about 100 basis points year over year. And the actions that we've defined as we said with the cost takeout should be about 200 basis points right there. So that would put us well above 25% if you will for the business. And that's prior to any further mix enhancements or if you will, growth leverage on our say fixed asset core. So we think the 25% to 27% is an appropriate target and we're comfortable that we can get there. Like, like the cost out discussion, as we, as we achieve that solidly, think that begins to be the time where we may want to talk about the opportunities to to go beyond it. But right now, we'd like to stay focused on executing on the plan to achieve the targets. And you're you're right. I mean, you can get to the point where you begin to give up business if you are strictly pursuing, if you will, a margin profile. But I would go back to that is, if you will, one of the beauties of associating our commercial team with this this construct of volume as it impacts absorption mix and price versus raw is that we can make those trade offs understanding how we can improve our GP percent without simply moving to to business, which is of a higher GP percent. So for example, if we decided to exit a big slug of because it was not at, on our margins because we would lose absorption. So again, making the system healthy involves pricing. It involves mix and it involves growth and successful asset utilization. And, and I think we've got plenty of runway, but, but, please understand, we're heads down focusing on executing our agenda. And, you know, we don't we don't want to get too far out over our skis. Let's let's deliver these. And as we we move along next year, I think we'll be in a better position to talk about, you know, the additional steps we'll be taking to enhance the business. Mike, as you look at the, as you look at the outlook that we provided, if you just kind of center on the midpoint of the range in terms of revenue growth and and the EBITDA for the business for fiscal 'nineteen. On a full year basis, we'll be a we should be approaching that 25 percent EBITDA margin, baseline that we've talked about for the full year, keeping in mind that we're call it, 23 and change this year. That would represent a pretty significant improvement and put us in a great spot to, to then move forward as we layer in the remaining cost out within ASI plus organic growth to really to really get into that that 26, 27% range, you know, within within the next, you know, call it 1 to 2 years. And that's that's a, that's a really good place to be. Got it. And then quick follow-up on the sale of composites and Marl If you signed the agreement in this quarter, can you discontinue that business and then in the quarter, or does that have to happen when you actually sell the business? And then, you know, why do you have any with the proceeds, I understand you want to pay down debt, but are there opportunities to continue to add, you know, businesses, pharma cans to the portfolio when you look at the M and A, environment? And in in terms of the accounting treatment, it's our expectation that when we decide when we do sign a definitive agreement, we would we would move we'd move the business to discontinued operations in in the quarter that we signed that. And so, obviously, we'd we'd expect our current expectations would be to do that this quarter. And then we'll we'll recast the business and the results of the business as a result of that. And we'll provide updated guidance and and all that just to just as I mentioned, a few minutes ago on the call. I'll I'll let I'll address the acquisition piece, but the the thing I would, you know, the the thing I would mention is that in addition to the proceeds from the sale of the business, which again, primarily we will use to strengthen our balance sheet, which will give us a lot of optionality going forward. We're going to generate a lot of free cash flow. That can be used for a variety of purposes, whether it's, you know, bolt ons or or share repurchase of what have you. I think Kevin captured it well. And, you know, Pharmachem, we're very excited about the opportunity. It was a point in time opportunity, unique opportunity. As we go forward, as I'm trying to emphasize, our focus is on executing on our core agenda. And when we are down at 2.5 times on leverage and we're producing cash in excess. We have optionality as to what we can do. We have a large share repurchase, authorization as well that's that's there. But but I think at that point, once we have shown the continued growth delivered on our SG and A reductions, made the portfolio change that'll be the time to think more about how we further augment the business and bolt on things that may have a good strategic fit So so that may be be out there, but unless it's very opportunistic, we we wouldn't be taking actions in the near term, at least not not sizable actions. We want to deliver on this agenda. Thank you so much. Our next question comes from Rosemarie Morbelli with Gabelli and Co. Your line is now open. Thank you. Good morning, everyone. Good morning. I was wondering, you did give us some details on personal care and particularly the oral side. But I was wondering if you could talk about the trends you see between consumer and industrial businesses in the 2019 similar to 2018, increasing the, declining. Could you talk about that? Certainly. In the in the pharma area, we we see continued growth. We talked about kind of the the broad macro expectation would be around 5%, but we're still seeing the benefit of the new capacity and and some new products which we brought to the market. In personal care, we'll see outside of oral, I think, continued and similar growth to what we saw in fiscal year 'eighteen. We're having a lot of good success as it relates to delivering, the the biofunctionals are being very well received in those mark places and we have a number of launches, which which we're very excited about. In adhesives, we've been able to grow the business with some new product introductions. We've been able to to gain some share, and we've also been able to move price. And that would be our expectation for the future. And and in coatings, I think we've shown the ability to, to grow. That's an area that, we, we've had great success with. We've got new product launches. As you as you see and read from other companies around the globe, there there are Peaks And Valleys, if you will, to some degree and from a demand standpoint within those businesses. So we'll have to see how strong the architectural market is before we, if you will, throw down the gauntlet related to, you know, the rate of growth within that business. We see fundamentally in the energy business continued, demand and, growth in in the nutrition business. That's one where we we have a strong focus from an asset utilization standpoint and and so we have a focused effort and we'd like to to drive additional growth across that front. So There's there's nothing inherently in any of our markets that would give us pause other than in the oral care, which we have described, you know, specifically with us specific dynamic? Yeah. And, something that I think is worth mentioning around coatings specifically. We get we get asked this question, periodically and, and we are, we are all about architectural coatings. So I think, you know, water based paint, we, we have no exposure to automotive or or other solvent based coatings within our, you know, within our coatings business. And we do get asked that question periodically, and there's there's no exposure there. Okay. Great. Thank you. And if you have given us $200,000,000 worth of CapEx, anticipated for 2019, how much is going to stay with you? Is this, because I am assuming that some of that 200 is dedicated to composites and INS? Yeah, Rosemarie, approximately $160,000,000 of that would be, would be remaining with the business, about 40 would would go would go with, divested businesses. So think of the kind of a go forward as around 160,000,000 And probably 125 to 140 or so of that is maintenance stay in business, compliance type capital, The remainder is, you know, profitability improvement and a bit of growth capital for, you know, for some of our, constrained assets, which frankly, we don't have very many of right now given the new farm and capacity, but that's the that's the way to think about that. Okay. Thanks. And quickly, if I may, you are giving us a target of 25 to 7 to 27 percent, EBITDA margin for ASI if we look at the company post the divestitures, what would be the consolidated, margin Well, I think we'll we'll certainly, if you will, recast when we move to discontinued operations. And and have the profile of the transaction, if you will, clear. And so that may be the time to revisit your your question, Kevin, unless you have anything to add. No, I, I think, I think that's fair. I mean, the, the way, the way to, the, the way to think about it is, is we have the ASI business and you know with the EBITDA margin of that as on trailing 12 basis and what we expect that to do in fiscal 'nineteen. Within within the INS business, we'll be retaining the Lima facility. We use probably 2 thirds of Lima for internal production within ASI. The remaining goes to merchant market. In the form of BDO and and other derivatives. So you can look at the INS segment and kind of see what the EBITDA margin is for that and and get an idea of how that impacts the overall. And then, you you look at the assumption around the the the corporate unallocated, and that would be the 3rd piece of that puzzle. So you can you can pretty easily I think model, you know, model around that. Okay. Thank you. Sure. Thank you so much. Our following question comes from Mike Harrison with Seaport Global Securities. Your line is now open. Hi, good morning. Good morning. I'm just looking at the EBITDA guidance for the ASI business, keeping in mind that you've got $20,000,000, worth of incremental cost savings in there. It really doesn't seem to imply a whole lot of the fixed cost leverage or the mix improvements or the the price versus cost. Improvement, that we might be expecting as we look at 19 versus 18. So is is there just a little bit of conservatism in there or or is this really the the headwinds from Colgate and, and FX, that that you're sort of baking in there that anything else we need to keep in mind for for headwinds there? Yeah. First of all, in in the spirit of the leverage, we try to avoid the use of the word headwinds these days. You know, there are things that come across our path and we have to overcome them. But in the spirit of your question, if you will, the, we put out a range and, and obviously, that range is, is for a reason. There are are quite a number of things that, we feel very good about in terms of how we're we're developing the the business and the pricing actions and the increased absorption, the mix improvements. What, we also do see is the, the, FX and raw materials. It is a a bit of a volatile global environment. Just from a trade standpoint, we're not forecasting those as being significant problems. If you will related to our earnings. So that's why I think we've put together what we think is an appropriate and achievable target as well as if you will arrange that would give us an opportunity to, you know, of course, we can can over deliver. We'd love to do that. We may also face some challenges, but but we're focused on on at least, delivering the center of the range of our target. And if you if you look at the range, I mean, what we're what we're implying is in in spite of oral care, in spite of FX, midpoint of the range would imply 5% year over year EBITDA growth. And I think one of the things to keep in mind in in the Special Ingredients business the DAA portion of EBITDA is about 40% or so. So that would imply double digit EBIT growth for the business. And you you layer the $20,000,000 on top of that, you get you get EBITDA growth, north of 8% at the midpoint of the range. Which, you know, we feel quite comfortable is is very strong. Alright. And, with regard to the the Colgate business. Did you have some exclusivity with them, that you're now free to potentially go after some other customers, for Gantres in oral care. Just trying to think about the pace of, of overcoming that, obstacle. Sure. Sure. It wasn't so much that it was, an exclusive. It was a unique formulation that, they, they provided to the marketplace and and the material that is is used for that formula is is not used broadly or the materials used broadly, but not not in the purpose, if you will, that, that Colgate used it. And so This is is really, if you will, we believe, contained to this relaunch, which is significant, but, this re re launch. And, and it's unlikely and we don't see on the horizon that that others will now, if you will, change their formulation, which would be, you know, a move to to an older formulation that's being relaunched right now. So, we we view this as it. Again, the it's it's not being replaced by, another material It's just that the new formulation doesn't need the Cantres as we go forward. Alright. And just really quickly, you've met the D and A component is pretty large within ASI. I was wondering though the D and A number for fiscal 'eighteen was closer to 300,000,000 and you're guiding to $2.85 for fiscal 'nineteen. What's driving that reduction? It's real it's really the I and S business as much as anything. Composites has pretty pretty low DNA. But as, you know, as as we've, as we as we move through this, it's it's really more the I and S business. Alright. Thanks very much. Thank you. Thank you. Our next question comes from Lawrence Alexander from Jefferies. Your line is now open. Hi, there. Can we, flesh out the margin discussion from slightly different angle as you think about the end market that ASI sells into and that that you'll give up the updates on on the quarterly calls. How stable are have the margins been in each of those channels and then I guess the second related question is as you think longer term, once you get the margin structure to sort of a stable run rate, do you see, a chance to accelerate structurally improve the growth rate for ASI by 100, 200 basis points I'll maintain while while selling into higher margin products, or is there going to be a trade off between faster growth and the margin profile? Yeah. So from a a margin profile standpoint, we haven't seen, if you will, significant trends, at least in last fiscal year. There are some areas where we've seen seen it increase, some areas where we've seen, you know, a little bit of all a follow-up. But in general, when you look in the aggregate, it's been fairly constant, but that's been in the context of significant raw material inflation. And so as we say, we have a a quarter or 2, lag typically to recover that. And so we've been able to, if you will, overcome that on the basis of our mix improvements along with our, our, absorption and manufacturing benefits that we focused on. So That's been the formula for last year. As we move forward, it's always a challenge to predict what raw materials will do in the future, but as we push pricing through on our existing products, we still intend to drive a richer mix. We intend to to drive better utilization of our assets. And so that would be an opportunity in the future for us to in enhance our margins. We do still have raw material inflation that's that may abate over time, but at this point is, is greater in fiscal year 2019 over 2018. But our, we've included that in our outlook. So we I I don't see a significant trade off, in terms of volume versus, if you will, profitability. We do have some places where we do things like purchase for resale and, you know, very low margin activities where you know, frankly, it's it's better for us just to to gracefully exit the the, segments. But in, in general, because of the variable economics on our system, you know, even even if it's not quoted, the system average GP percent, If we're if we're basically running that off of an existing asset with available capacity, the the variable economics allow us to maintain the GP percent in that context. And we look forward to the day when all of our assets are pulling, we, we have to make, good choices about whether to expand them. But frankly, a number of our assets. It would be nice just to focus on upgrading the mix. And at that point, that would be the trade off. Yeah. Lawrence, if you look at it at a at a high level, today, we we characterize the business as consumer and industrial specialties. And, we we generally see a higher growth rate on the consumer side, which is also generally a higher margin part of the business. And with with a strategy to continue to, to grow that faster while obviously still growing the industrial business because that covers, frankly, you know, the vast majority of fixed costs plus nice profitability on top of it. We we see that as a strategy that will continue to work and and should not see profitability trade offs as a as a result of that. Our final question comes from Jim Sheehan with SunTrust. Your line is now open. Thanks. Good morning. Could you provide some more color on trends you're seeing in adhesives. It looks like you, you've had some pretty good, demand year to date. Are you seeing any, evidence of destocking in that area? And, and I, I presume your stronger growth rate is due to market share gain. If you could just provide more color on adhesives. Thank you. Yes. So one of the things we've we've seen is, a revenue increase. We've had significant raw material inflation in this area team has worked aggressively selling the value equation to make sure to offset that and they've done a very nice job. We have picked up some share in some new areas with some new technologies and that's also helping to bolster the growth. So that's really been the formula of success for that business. And We'd love to see raw materials abate so we could just focus more energy on, driving the innovation and gaining share in that market, in, as we go into fiscal year 'nineteen. And, Jim, if you look at our adhesives business, we we've we've been in the adhesives business for quite some time. And over over the course of of history, If you if you level out some, you know, customer gains, customer losses that occasionally occur, that's that business has consistently grown at mid single digits. It's very niche. It plays in some very specialized end markets and the technology we provide and the tech service that we provide really, really allows us to grow that business at that rate. There's, you know, virtually no commoditized adhesives in that business. We don't play in that space And and as as such, you know, historically, that business has been, you know, nicely profitable and a good grower. And we'd expect that to continue. Terrific. And in your 2019 outlook, can you talk about what you're anticipating for trade and tariff impacts? Are you seeing any effects on your supply chains or end markets? There is some, some impact that we've we've seen from tariffs. I mean, I'm talking about the tariffs themselves as m materials have moved. I think you you can recognize that, mean, we all recognize that the effect that it has on, on, if you will, GDP growth within specific regions can affect us like it could affect anybody else, but we're we're not having a tremendous amount of activity of moving materials from the USA to China and back. We do have some materials. We also have potential sources of those within our system, say, from from a European perspective and so forth. So, obviously, we're all interested in and seeing how this plays out, but we're we're not calling that out as something that we see as, problematic unless it affects really the overall macro demand for for products in general. Thank you. I'm showing no further questions at this time. I would now like to turn the call back to Seth Mrazo for closing remarks. Thank you, Sydney. Thank you all for your time this morning, and thank you for your interest in Ashland. Have a great day. Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone have a great day.